Breaking News Instant updates and real-time market news.

NAVI

Navient

$10.74

-1.255 (-10.47%)

05:21
11/21/18
11/21
05:21
11/21/18
05:21

Navient CEO sends letter to holders in response to AP article

Navient released the following letter from Jack Remondi CEO, to company shareholders: "Today's article by the Associated Press continues the practice of ignoring facts to make false, sensational and harmful accusations that discourage borrowers from working with their servicers. Despite being in possession of the Federal Student Aid, or FSA, review and our account-by-account response, the article repeated a series of false accusations that are not found in any section of the review. A full reading of the report, our responses included in the report and comments provided by the U.S. Department of Education clearly and unequivocally refute the accusations that Navient was improperly steering borrowers. They also affirmatively conclude that in those instances where forbearance was used, it was applied appropriately. According to a Department of Education statement on the review: ...in approximately 9 percent of those calls, it was not clear whether Navient had sufficiently discussed options with the borrower. In response to FSA's preliminary conclusions, Navient provided detailed information about each of the calls at issue. Based on FSA's review of Navient's responses and FSA's independent review of Navient's overall performance, FSA has concluded that Navient is substantially in compliance with its obligations. The article also claims that the CFPB and others did not possess the report (though later it admits they did). In fact, the review has been in the hands of the CFPB and state AGs for nearly a year. One of the main claims is that enrolling borrowers in forbearance is an inappropriate and therefore deceptive practice. This conclusion is deceptive in itself and shows a lack of understanding of the different repayment options available to borrowers and how forbearance can be both a proper and lower cost option for borrowers. It also ignores the fact that the option of forbearance was authorized by Congress and no senator has initiated any bill to eliminate it as a valid option. A full reading of the review and our response makes it clear that we discussed options other than forbearance or that forbearance was the most appropriate option choice for the borrower. Navient provided these details to Senator Warren in a letter dated November 15, 2018. The letter, which we are releasing at navient.com/legalfacts in response to the Senator's press release makes clear that the accusations are false and misleading and are a blatant attempt to discredit the good work of my 6,000-plus dedicated colleagues. The Department of Education statement continued: Program data indicated that Navient's overall use of forbearance was consistent with that of other servicers, while the duration of forbearances for Navient borrowers was actually among the lowest of the Department's nine servicers. Navient also had among the highest take-up rates for income-driven repayment plans, as well as longer than average call durations in comparison to all servicers. The federal loan programs offer over 50 different repayment options. Some are designed for long-term challenges and others are designed to address short-term challenges. Contrary to some views, no single option is always best or always worst. It always depends on the borrowers' unique circumstances. The most expensive option is doing nothing and allowing the account to become delinquent and/or default. At Navient we help our customers select the option that best fits their needs. The results are crystal clear, borrowers serviced by Navient have the highest enrollment in income-driven repayment programs of all comparable servicers and are least likely to default. We are proud of these industry leading results and I am proud of the work our team does each and every day to assist borrowers. It is deeply sad that these false accusations are spread without facts to support them and, as a result, borrowers are discouraged from engaging with their services. Nevertheless, we will continue to provide quality service to help our customers succeed."

  • 29

    Nov

NAVI Navient
$10.74

-1.255 (-10.47%)

04/04/18
COMP
04/04/18
UPGRADE
COMP
Buy
Navient upgraded to Buy from Neutral at Compass Point
04/05/18
COMP
04/05/18
UPGRADE
Target $15.5
COMP
Buy
Navient upgraded to Buy from Neutral at Compass Point
Compass Point analyst Mike Tarkan upgraded Navient to Buy from Neutral, as he believes improving credit trends, an increasing mix towards refi loans, and lower provision expenses can drive earnings higher over the next several years. He also thinks the private student loan portfolio may hit an inflection point in late 2020 and resume growth from there. Tarkan maintains a $15.50 price target on Navient shares.
06/01/18
WEDB
06/01/18
UPGRADE
WEDB
Outperform
Navient upgraded to Outperform from Neutral at Wedbush
06/01/18
06/01/18
UPGRADE
Target $15.75

Outperform
Navient upgraded to Outperform with $15.75 price target at Wedbush
As previously reported, Wedbush analyst Henry Coffey upgraded Navient to Outperform from Neutral, stating that the company's new reporting structure helps him better appreciate the company's earnings outlook and suggests the company is likely to report modest growth in EPS and a total return of over 18% during the next 18 months. Coffey raised his estimates for Navient and increased his price target on the stock to $15.75 from $14.50.

TODAY'S FREE FLY STORIES

10:01
12/17/18
12/17
10:01
12/17/18
10:01
General news
Housing Market Index data reported »

December Housing Market…

UGAZ

VelocityShares 3x Long Natural Gas ETN

$84.44

-7.56 (-8.22%)

10:00
12/17/18
12/17
10:00
12/17/18
10:00
Hot Stocks
VelocityShares 3x Long Natural Gas ETN falls -8.3% »

VelocityShares 3x Long…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNC

Centene

$116.87

-10.68 (-8.37%)

10:00
12/17/18
12/17
10:00
12/17/18
10:00
Hot Stocks
Centene falls -8.4% »

Centene is down -8.4%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

MOH

Molina Healthcare

$111.84

-19.88 (-15.09%)

10:00
12/17/18
12/17
10:00
12/17/18
10:00
Hot Stocks
Molina Healthcare falls -14.7% »

Molina Healthcare is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBD

Banco Bradesco

$9.67

-0.08 (-0.82%)

10:00
12/17/18
12/17
10:00
12/17/18
10:00
Options
Bearish option flow in Banco Bradesco »

Bearish option flow in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DGAZ

VelocityShares 3x Inv Natural Gas ETN

$84.90

6.21 (7.89%)

10:00
12/17/18
12/17
10:00
12/17/18
10:00
Hot Stocks
VelocityShares 3x Inv Natural Gas ETN rises 8.1% »

VelocityShares 3x Inv…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CDE

Coeur Mining

$4.13

0.31 (8.12%)

10:00
12/17/18
12/17
10:00
12/17/18
10:00
Hot Stocks
Coeur Mining rises 8.7% »

Coeur Mining is up 8.7%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGI

Alamos Gold

$3.24

0.275 (9.27%)

10:00
12/17/18
12/17
10:00
12/17/18
10:00
Hot Stocks
Alamos Gold rises 9.1% »

Alamos Gold is up 9.1%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DFFN

Diffusion Pharmaceuticals

$2.89

0.02 (0.70%)

09:59
12/17/18
12/17
09:59
12/17/18
09:59
Hot Stocks
Diffusion Pharmaceuticals awarded patent for use of TSC in conjuction with tPA »

Diffusion Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IP

International Paper

$42.41

-0.98 (-2.26%)

09:57
12/17/18
12/17
09:57
12/17/18
09:57
Options
International Paper put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HUM

Humana

$298.75

-1.66 (-0.55%)

, UNH

UnitedHealth

$258.80

-6.26 (-2.36%)

09:56
12/17/18
12/17
09:56
12/17/18
09:56
On The Fly
Healthcare, hospital stocks slide as judge rules ACA 'unconstitutional' »

Major healthcare and…

HUM

Humana

$298.75

-1.66 (-0.55%)

UNH

UnitedHealth

$258.80

-6.26 (-2.36%)

CNC

Centene

$115.98

-11.57 (-9.07%)

AET

Aetna

$0.00

(0.00%)

ANTM

Anthem

$268.16

-7.43 (-2.70%)

CI

Cigna

$199.97

-5.37 (-2.62%)

HNT

Health Net

$0.00

(0.00%)

HCA

HCA Healthcare

$120.30

-6.36 (-5.02%)

THC

Tenet

$19.92

-1.32 (-6.21%)

CYH

Community Health

$3.61

-0.305 (-7.79%)

MOH

Molina Healthcare

$111.98

-19.74 (-14.99%)

WCG

WellCare

$224.83

-12.07 (-5.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

  • 10

    Jan

  • 05

    Feb

  • 19

    Feb

09:55
12/17/18
12/17
09:55
12/17/18
09:55
General news
U.S. NAHB housing market index preview: »

U.S. NAHB housing market…

VUZI

Vuzix

$5.51

(0.00%)

09:52
12/17/18
12/17
09:52
12/17/18
09:52
Hot Stocks
Vuzix announces voluntary dismissal of class action lawsuit »

Vuzix is pleased to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CDE

Coeur Mining

$3.99

0.17 (4.45%)

09:47
12/17/18
12/17
09:47
12/17/18
09:47
Hot Stocks
Coeur Mining rises 4.5% »

Coeur Mining is up 4.5%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOL

Gol Linhas

$12.22

0.49 (4.18%)

09:47
12/17/18
12/17
09:47
12/17/18
09:47
Hot Stocks
Gol Linhas rises 4.9% »

Gol Linhas is up 4.9%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DGAZ

VelocityShares 3x Inv Natural Gas ETN

$85.21

6.52 (8.29%)

09:47
12/17/18
12/17
09:47
12/17/18
09:47
Hot Stocks
VelocityShares 3x Inv Natural Gas ETN rises 8.0% »

VelocityShares 3x Inv…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:45
12/17/18
12/17
09:45
12/17/18
09:45
General news
FOMC Checklist: »

FOMC Checklist: The FOMC…

09:45
12/17/18
12/17
09:45
12/17/18
09:45
General news
Housing Market Index to be reported at 10:00 »

December Housing Market…

CMLS

Cumulus Media

$10.75

(0.00%)

09:40
12/17/18
12/17
09:40
12/17/18
09:40
Upgrade
Cumulus Media rating change  »

Cumulus Media upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBD

Banco Bradesco

$9.75

(0.00%)

, NOK

Nokia

$5.94

(0.00%)

09:40
12/17/18
12/17
09:40
12/17/18
09:40
Options
Unusually active option classes on open December 17th »

Unusual total active…

BBD

Banco Bradesco

$9.75

(0.00%)

NOK

Nokia

$5.94

(0.00%)

NIO

NIO Inc.

$7.67

(0.00%)

T

AT&T

$30.24

(0.00%)

VXX

iPath S&P 500 VIX Short-Term Futures

$40.53

(0.00%)

DIA

Diamonds Fund ETF

$241.50

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

  • 20

    Mar

JNJ

Johnson & Johnson

$132.86

-14.94 (-10.11%)

09:39
12/17/18
12/17
09:39
12/17/18
09:39
Technical Analysis
Technical Take: Johnson & Johnson extends recent fall »

Shares are down over 3.6%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jan

ZEAL

Zealand Pharma

$13.19

(0.00%)

09:39
12/17/18
12/17
09:39
12/17/18
09:39
Downgrade
Zealand Pharma rating change  »

Zealand Pharma downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:37
12/17/18
12/17
09:37
12/17/18
09:37
General news
Friday selloff spills into new week »

Stock futures fell during…

ALTM

Altus Midstream Company

$8.72

-0.71 (-7.53%)

09:35
12/17/18
12/17
09:35
12/17/18
09:35
Hot Stocks
Breaking Hot Stocks news story on Altus Midstream Company »

Altus Midstream Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARMK

Aramark

$32.07

-0.63 (-1.93%)

09:33
12/17/18
12/17
09:33
12/17/18
09:33
Periodicals
Breaking Periodicals news story on Aramark »

Aramark mentioned…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.